Rate My Professor Carolyn Bertozzi

Her research focuses on fundamental studies of disease-associated glycobiology and the development of new therapeutic modalities targeting these pathways. She pioneered bioorthogonal chemistries for in vivo imaging and bioconjugation, work recognized by the 2022 Nobel Prize in Chemistry, which she shared with K. Barry Sharpless and Morten P. Meldal. Her laboratory has developed next-generation antibody-drug conjugates, lysosome-targeting chimeras, antibody-enzyme conjugates, and antibody-lectin chimeras, several of which have advanced to clinical candidates for cancer and autoimmune diseases. Bertozzi has authored or co-authored more than 600 publications. She is an elected member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Engineering, the American Academy of Arts and Sciences, the German Academy of Sciences Leopoldina, and a Foreign Fellow of the Royal Society. Additional honors include the Priestley Medal, the Welch Award, the Wolf Prize in Chemistry, the Heineken Prize, the Lemelson-MIT Prize, and a MacArthur Fellowship.